drugset / Trial / NCT00005052

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

NCT00005052

RandomizedOpen-labelTreatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether vaccine therapy is more effective than observation alone for melanoma. PURPOSE: This randomized phase III trial is studying vaccine therapy to see how well it works compared to observation alone in treating patients with primary stage II melanoma.

Timeline

Start
1999-12
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject GM2-KLH Vaccine Subcutaneous
Subject QS-21 Other / unclassified Subcutaneous

Indications